Continued Access to Elotuzumab for Participants from Previous Studies

Sponsor: Bristol-Myers Squibb

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT02719613

Provider View

This study allows participants who were part of earlier trials involving the drug elotuzumab to continue receiving the medication if they are benefiting from it and cannot access it commercially.

Patient Parameters

Program Overview

The aim of this study is to provide ongoing access to the drug elotuzumab, and possibly other study medications, for participants who were involved in previous trials of elotuzumab and are experiencing positive effects from the treatment. This is for those who cannot obtain the drug through commercial means.

Eligibility Criteria

Inclusion Criteria

  • Previously participated in an elotuzumab study (such as HuLuc63-1703, CA204007, CA204009, or CA204011) and are benefiting from the treatment according to the study's criteria.
  • Currently receiving elotuzumab or other study medications at the time of signing the consent form.
  • Open to both men and women aged 18 and older.

Exclusion Criteria

  • Participants who stopped participating in an elotuzumab study for any reason.
  • Participants who did not benefit from the previous study treatment.
  • Participants who are not in good enough health to continue receiving the study treatment, as determined by the study doctor.

Other specific criteria may apply.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.